• Cancel
    Date：2020-09

    -

  • Cancel
    Date：2020-09

    CEC Capital Served as Financial Advisor

  • Cancel
    Date：2020-09

    CEC Capital Served as Financial Advisor

  • Cancel
    Date：2020-08

    -

  • Cancel
    Date：2020-08

    CEC Capital Served as Financial Advisor

  • Cancel
    Date：2020-08

    CEC Capital Served as Financial Advisor

  • Cancel
    Date：2020-07
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=462

    Shanghai, 27 July 2020— Shanghai Haihe Pharmaceutical Co., Ltd (hereinafter referred to as "Haihe Pharmaceutical"), a leading biotech company focuses on the discovery and development of innovative drugs for cancer, announced today that it has closed ￥1.20 Billion Series B Financing. This round of financing was led by Warburg Pincus, joined by CMBI, Legend Capital, CICC Capital, Chaos Investment, ALAN Asset Management, Ruihua Investment, SSC and Series A investors BioTrack Capital, Yingke PE, Atlas Capital, CSPC and affiliated parties. The company intends to use the funds to advance its pipeline, which includes the ongoing R&D and commercialization of multiple anti-tumor innovative drugs worldwide. CEC Capital served as the exclusive financial adviser to Haihe Pharmaceutical during this round of financing.

  • Cancel
    Date：2020-07
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=435

    CF PharmTech, Inc., a pharmaceutical company with a vision to provide quality and affordable respiratory drug products globally, announced it has raised a $90 million Series E investment led by New Alliance Capital. The investment included participation f

  • Cancel
    Date：2020-06

    CEC Capital Served as Financial Advisor